GlobeNewswire·Nov 5, 2026, 8:10 PM ET

Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

Perspective Therapeutics presented incremental Phase 1/2a data on [212Pb]VMT-α-NET (bamzireotide) at the NANETS 2026 symposium on November 5, 2026.
Analyses of 57 gastroenteropancreatic (GEP) NET patients with SSTR2+ target lesions showed a 75% progression-free survival rate at 18 months.
Disease control rates reached 92% in Cohort 2 (35 of 38 patients) and 100% in Cohort 3 (17 of 17 patients).
Objective response rates were 37% (14 of 38) for Cohort 2 and 47% (8 of 17) for Cohort 3.
The drug demonstrated a strong safety profile with no dose-limiting toxicities, no treatment-related discontinuations, and no Grade 4 or 5 adverse events.
High-grade treatment-emergent adverse events occurred in 29% of patients, while high-grade hematologic events occurred in 7.4% of patients.
Perspective Therapeutics plans to incorporate SSTR2 enrichment strategies into registration study designs.
The company targets an End-of-Phase 2 meeting with the FDA in the first quarter of 2027.
A Phase 3 study initiation is expected in 2027 following FDA feedback.
The company will present a poster on bamzireotide at the EORTC-NCI-AACR Symposium on November 20, 2026.